21.21
price up icon4.23%   0.86
after-market Dopo l'orario di chiusura: 21.29 0.08 +0.38%
loading
Precedente Chiudi:
$20.35
Aprire:
$20.31
Volume 24 ore:
1.83M
Relative Volume:
2.02
Capitalizzazione di mercato:
$1.39B
Reddito:
$9.98M
Utile/perdita netta:
$-154.08M
Rapporto P/E:
-8.2209
EPS:
-2.58
Flusso di cassa netto:
$-159.66M
1 W Prestazione:
-2.03%
1M Prestazione:
+7.23%
6M Prestazione:
-16.07%
1 anno Prestazione:
-45.60%
Intervallo 1D:
Value
$20.01
$22.32
Intervallo di 1 settimana:
Value
$19.52
$22.32
Portata 52W:
Value
$14.40
$47.00

Celldex Therapeutics Inc Stock (CLDX) Company Profile

Name
Nome
Celldex Therapeutics Inc
Name
Telefono
908-200-7500
Name
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Name
Dipendente
186
Name
Cinguettio
@search?q=celldex
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
CLDX's Discussions on Twitter

Confronta CLDX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CLDX
Celldex Therapeutics Inc
21.21 1.39B 9.98M -154.08M -159.66M -2.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-28 Iniziato Canaccord Genuity Buy
2025-03-20 Iniziato Morgan Stanley Overweight
2025-02-13 Iniziato UBS Buy
2024-10-07 Iniziato Citigroup Buy
2024-09-30 Iniziato Goldman Neutral
2024-09-27 Downgrade Wolfe Research Outperform → Peer Perform
2024-06-18 Iniziato Stifel Buy
2024-06-11 Iniziato Wolfe Research Outperform
2023-12-20 Iniziato TD Cowen Outperform
2023-11-10 Aggiornamento Wells Fargo Underweight → Equal Weight
2023-08-22 Iniziato Wells Fargo Underweight
2021-09-17 Iniziato Jefferies Buy
2021-09-10 Iniziato SVB Leerink Outperform
2021-07-22 Iniziato Guggenheim Buy
2020-02-21 Iniziato Cantor Fitzgerald Overweight
2017-08-01 Ripresa H.C. Wainwright Buy
2016-11-07 Iniziato Aegis Capital Buy
2016-03-08 Downgrade Jefferies Buy → Hold
2016-03-07 Downgrade Guggenheim Buy → Neutral
2016-03-07 Downgrade Leerink Partners Outperform → Mkt Perform
2016-03-07 Downgrade Wedbush Outperform → Neutral
2016-03-01 Iniziato H.C. Wainwright Buy
2015-08-11 Reiterato Brean Capital Buy
2015-08-11 Reiterato Oppenheimer Outperform
2015-08-11 Reiterato ROTH Capital Buy
2015-06-02 Reiterato WBB Securities Strong Buy
2014-11-17 Reiterato ROTH Capital Buy
2014-03-04 Reiterato Oppenheimer Outperform
2013-07-08 Reiterato Cantor Fitzgerald Buy
2013-03-08 Reiterato Cantor Fitzgerald Buy
2013-02-26 Reiterato Oppenheimer Outperform
2013-01-10 Reiterato Cantor Fitzgerald Buy
2012-10-02 Reiterato Oppenheimer Outperform
2012-09-14 Reiterato Cantor Fitzgerald Buy
Mostra tutto

Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie

pulisher
Jun 16, 2025

Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World

Jun 16, 2025
pulisher
Jun 15, 2025

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.

Jun 14, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News

Jun 13, 2025
pulisher
Jun 13, 2025

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Transcript : Celldex Therapeutics, Inc.Special Call - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: Celldex CSU Drug Maintains Complete Response 7 Months After Treatment Ends - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex stock rating reiterated at Buy by Canaccord ahead of data release - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 11, 2025

One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - simplywall.st

Jun 11, 2025
pulisher
Jun 11, 2025

Eric Sprott buying at Silver Storm Mining (SVRS) - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for CLDX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

Groundbreaking 76-Week Chronic Urticaria Treatment Data: Celldex's Barzolvolimab Results Coming to EAACI - Stock Titan

Jun 10, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics appoints new board member By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics Appoints Denice Torres To Board - citybiz

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics appoints new board member - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Approves Equity Plan Amendment and Elects New Director - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance

Jun 06, 2025
pulisher
May 28, 2025

Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy - openPR.com

May 28, 2025
pulisher
May 26, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com

May 23, 2025
pulisher
May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com India

May 23, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 19, 2025
pulisher
May 13, 2025

Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks

May 13, 2025
pulisher
May 12, 2025

Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World

May 12, 2025
pulisher
May 11, 2025

Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 11, 2025
pulisher
May 11, 2025

Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus

May 11, 2025
pulisher
May 10, 2025

UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus

May 10, 2025
pulisher
May 10, 2025

First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 10, 2025
pulisher
May 09, 2025

H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus

May 09, 2025

Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):